Ozempic being a household name, GLP-1 receptor agonists (GLP-1RAs), a class of medications have garnered significant ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

FILE - The injectable drug Ozempic is shown Saturday, July 1, 2023, in Houston. Even as millions of older adults clamor for drugs such as Ozempic and Wegovy, monthly use of the medications known as ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...

Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer over the short term.

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting ...

Study: Suicide and suicide attempt in users of GLP-1 receptor agonists: a nationwide case-time ... These results suggest that GLP-1 RA use does not increase the risk of suicidal behaviors, even ...

That is perhaps why there has been so much buzz surrounding the class of drug known as a GLP-1 agonist.

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

"It is estimated that by 2030, 30 million GLP-1 [receptor agonist] prescriptions will have ... What should eye doctors do in light of the case series and other reports? "Because of the association ...

Kidney stones are among the possible risks of GLP-1 use that were not previously known. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) may have a wider range of benefits and risks than what ...